{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:10:12Z","timestamp":1791259812853,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clim.2022.109186","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:24:13Z","timestamp":1669047853000},"page":"109186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Treat to target in Behcet's disease: Should we follow the paradigm of other systemic rheumatic diseases?"],"prefix":"10.1016","volume":"246","author":[{"given":"George E.","family":"Fragoulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonca","family":"Mumcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilknur","family":"Tugal-Tutkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2022.109186_bb0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Behcet\u2019s disease: new insights into pathophysiology, clinical features and treatment options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2022.109186_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102882","article-title":"Sex-specific analysis in Behcet\u2019s disease reveals higher genetic risk in male patients","volume":"132","author":"Jo","year":"2022","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2022.109186_bb0015","article-title":"Genetics of Behcet\u2019s disease: functional genetic analysis and estimating disease heritability","volume":"8","author":"Ortiz-Fernandez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clim.2022.109186_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Behcet syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0025","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Behcet's syndrome: a systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2022.109186_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2022.109186_bb0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/ard.2010.128462","article-title":"\u2018Treat to target\u2019: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis","volume":"69","author":"Atar","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update","volume":"75","author":"Stoffer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0045","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","article-title":"Treat-to-target in rheumatoid arthritis - are we there yet?","volume":"15","author":"van Vollenhoven","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0055","first-page":"1453","article-title":"Highlights of the 19th international conference on Behcet\u2019s syndrome","volume":"40","author":"Esatoglu","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0060","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2010.135186","article-title":"Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update omicronn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0070","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2022.109186_bb0075","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic Lupus international collaborating clinics (SLICC) inception cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0080","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/rheumatology\/ket171","article-title":"Predictors of self-reported health-related quality of life in systemic lupus erythematosus","volume":"52","author":"Kiani","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2022.109186_bb0085","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0090","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0095","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0100","first-page":"e95","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study, the lancet","volume":"1","author":"Golder","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2022.109186_bb0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","article-title":"Both prolonged remission and Lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus","volume":"56","author":"Tsang","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2022.109186_bb0110","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","article-title":"Prolonged remission in Caucasian patients with SLE: prevalence and outcomes","volume":"74","author":"Zen","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0115","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/annrheumdis-2016-210154","article-title":"The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients","volume":"76","author":"Zen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0120","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/annrheumdis-2020-217070","article-title":"Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort","volume":"79","author":"Saccon","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"2019","key":"10.1016\/j.clim.2022.109186_bb0130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"2020","key":"10.1016\/j.clim.2022.109186_bb0135","first-page":"713","article-title":"Update of the joint European league against rheumatism and European renal association-European Dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000516","article-title":"LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial","volume":"8","author":"Mucke","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.clim.2022.109186_bb0145","first-page":"2380","article-title":"Brief report: drug-free long-term remission in severe Behcet\u2019s disease following withdrawal of successful anti-tumor necrosis factor treatment, arthritis","volume":"69","author":"Sfikakis","year":"2017","journal-title":"Rheumatol"},{"key":"10.1016\/j.clim.2022.109186_bb0150","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/rheumatology\/keab581","article-title":"The assessment of presenteeism and activity impairment in Behcet's syndrome and recurrent aphthous stomatitis: a multicentre study","volume":"61","author":"Karacayli","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2022.109186_bb0155","series-title":"Disease Assessment in Beh\u00e7et Syndrome","first-page":"261","author":"Mumcu","year":"2020"},{"key":"10.1016\/j.clim.2022.109186_bb0160","first-page":"S80","article-title":"A new Mucocutaneous activity index for Behcet\u2019s disease","volume":"32","author":"Mumcu","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0165","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00296-018-4117-y","article-title":"The influence of oral health and psycho-social well-being on clinical outcomes in Beh\u00e7et\u2019s disease","volume":"38","author":"Senusi","year":"2018","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.clim.2022.109186_bb0170","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","article-title":"Behcet's disease: evaluation of a new instrument to measure clinical activity","volume":"38","author":"Bhakta","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2022.109186_bb0175","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10067-014-2585-3","article-title":"Unmet need in Behcet\u2019s disease: most patients in routine follow-up continue to have oral ulcers","volume":"33","author":"Alibaz-Oner","year":"2014","journal-title":"Clin. Rheumatol."},{"issue":"Suppl. 121","key":"10.1016\/j.clim.2022.109186_bb0180","first-page":"98","article-title":"Oral ulcer activity assessment with the composite index according to different treatment modalities in Behcet\u2019s syndrome: a multicentre study","volume":"37","author":"Mumcu","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Online ahead of print","key":"10.1016\/j.clim.2022.109186_bb0185","article-title":"Natural history of Behcet\u2019s disease focusing on remission of Oral ulcers","volume":"April 21","author":"Tomizuka","year":"2022","journal-title":"Mod. Rheumatol."},{"issue":"Suppl. 132","key":"10.1016\/j.clim.2022.109186_bb0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","article-title":"Apremilast for oral ulcers associated with active Behcet\u2019s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial","volume":"39","author":"Hatemi","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0195","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/1346-8138.15553","article-title":"Moderation analysis exploring associations between age and mucocutaneous activity in Beh\u00e7et\u2019s syndrome: a multicenter study from Turkey","volume":"47","author":"Mumcu","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.clim.2022.109186_bb0200","article-title":"Oral health and its Aetiological role in Beh\u00e7et\u2019s disease","volume":"697","author":"Mumcu","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.clim.2022.109186_bb0205","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bjoms.2020.07.027","article-title":"New mouthwash: an efficacious intervention for oral ulceration associated with Behcet\u2019s disease","volume":"58","author":"Senusi","year":"2020","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.clim.2022.109186_bb0210","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40265-019-01253-3","article-title":"Apremilast: a review in Oral ulcers of Behcet\u2019s disease","volume":"80","author":"Deeks","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2022.109186_bb0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1600-0714.2009.00803.x","article-title":"A composite index for determining the impact of oral ulcer activity in Behcet's disease and recurrent aphthous stomatitis","volume":"38","author":"Mumcu","year":"2009","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.clim.2022.109186_bb0220","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1600-0714.2009.00752.x","article-title":"Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behcet's disease","volume":"38","author":"Mumcu","year":"2009","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.clim.2022.109186_bb0225","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as remission induction therapy in Behcet disease: a 20-year experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0230","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10384-021-00872-2","article-title":"An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behcet\u2019s disease in long-term remission","volume":"65","author":"Ida","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.clim.2022.109186_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001192","article-title":"Development and preliminary validation of the Beh\u00e7et\u2019s syndrome overall damage index (BODI)","volume":"6","author":"Piga","year":"2020","journal-title":"RMD open"},{"key":"10.1016\/j.clim.2022.109186_bb0240","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/1756-185X.14166","article-title":"Development and validation of a Behcet's Disease Damage Index for adults with BD: An Explicit, Composite and Rated (ECR) tool","volume":"24","author":"Gheita","year":"2021","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0245","first-page":"931","article-title":"Development of the BD-QoL: a quality of life measure specific to Behcet\u2019s disease","volume":"31","author":"Gilworth","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0341-7","article-title":"Genital ulcer severity score and genital health quality of life in Beh\u00e7et\u2019s disease","volume":"10","author":"Senusi","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0260","series-title":"Disease Assessment in Behcet\u2019s Disease, Behcet\u2019s Syndrome","first-page":"299","author":"Mumcu","year":"2010"},{"key":"10.1016\/j.clim.2022.109186_bb0265","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/acr.24511","article-title":"Core Set of Domains for Outcome Measures in Behcet's Syndrome","volume":"74","author":"Hatemi","year":"2022","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2022.109186_bb0270","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3899\/jrheum.161352","article-title":"Developing a Core set of outcome measures for Behcet disease: report from OMERACT 2016","volume":"44","author":"Hatemi","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0275","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.131249","article-title":"Outcome measures used in clinical trials for Behcet syndrome: a systematic review","volume":"41","author":"Hatemi","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0280","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J. Ophthalmol."},{"issue":"2018","key":"10.1016\/j.clim.2022.109186_bb0285","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"Update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0290","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40942-021-00318-4","article-title":"Fluorescein angiographic findings and Behcet's disease ocular attack score 24 (BOS24) as prognostic factors for visual outcome in patients with ocular Behcet's disease","volume":"7","author":"Keorochana","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.clim.2022.109186_bb0295","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1080\/09273948.2019.1641611","article-title":"The relationship between fluorescein angiography leakage after infliximab therapy and relapse of ocular inflammatory attacks in ocular Behcet\u2019s disease patients","volume":"28","author":"Shirahama","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.clim.2022.109186_bb0300","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/kez352","article-title":"Clinical course of acute deep vein thrombosis of the legs in Behcet's syndrome","volume":"59","author":"Ozguler","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2022.109186_bb0305","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000494","article-title":"Behcet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses","volume":"94","author":"Alibaz-Oner","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clim.2022.109186_bb0310","first-page":"90","article-title":"Faecal but not serum calprotectin levels look promising in predicting active disease in Behcet\u2019s syndrome patients with gastrointestinal involvement","volume":"36","author":"Esatoglu","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0315","first-page":"CD011018","article-title":"Interventions for the management of oral ulcers in Behcet\u2019s disease","author":"Taylor","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.clim.2022.109186_bb0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00296-018-4193-z","article-title":"Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behcet\u2019s disease associated uveitis: a systematic review","volume":"39","author":"Urruticoechea-Arana","year":"2019","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.clim.2022.109186_bb0325","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet\u2019s disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.clim.2022.109186_bb0330","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0335","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clim.2022.109186_bb0340","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","article-title":"Interferon alpha-2a therapy in patients with refractory Behcet uveitis","volume":"25","author":"Hasanreisoglu","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.clim.2022.109186_bb0345","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.109186_bb0350","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","article-title":"Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet\u2019s disease with upregulation of circulating regulatory T cells and reduction of Th17","volume":"74","author":"Lightman","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2022.109186_bb0355","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2022.109186_bb0360","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.clim.2022.109186_bb0365","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.clim.2022.109186_bb0370","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","article-title":"Treatment of venous thrombosis associated with Behcet\u2019s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation","volume":"27","author":"Ahn","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0375","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/art.34450","article-title":"Immunosuppressants reduce venous thrombosis relapse in Behcet\u2019s disease","volume":"64","author":"Desbois","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2022.109186_bb0380","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","article-title":"Colchicine versus placebo in Behcet\u2019s disease: randomized, double-blind, controlled crossover trial","volume":"19","author":"Davatchi","year":"2009","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0385","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Behcet\u2019s syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2022.109186_bb0390","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clim.2022.109186_bb0395","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clim.2022.109186_bb0400","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2022.109186_bb0405","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for Oral ulcers in Behcet\u2019s syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.109186_bb0410","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Behcet's syndrome--a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.109186_bb0415","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","article-title":"A double-blind trial of depot corticosteroids in Behcet's syndrome","volume":"45","author":"Mat","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2022.109186_bb0420","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00126839-200304010-00002","article-title":"Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study","volume":"4","author":"Matsuda","year":"2003","journal-title":"Drugs R D"},{"key":"10.1016\/j.clim.2022.109186_bb0425","first-page":"98","article-title":"Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0430","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","article-title":"Dapsone in Behcet\u2019s disease: a double-blind, placebo-controlled, cross-over study","volume":"29","author":"Sharquie","year":"2002","journal-title":"J. Dermatol."},{"key":"10.1016\/j.clim.2022.109186_bb0435","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/mr\/roab008","article-title":"Apremilast in a Japanese subgroup with Behcet\u2019s syndrome: results from a phase 3, randomised, double-blind, placebo-controlled study","volume":"32","author":"Takeno","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0440","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Behcet\u2019s syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.109186_bb0445","first-page":"1500","article-title":"Adalimumab-based treatment versus disease-modifying Antirheumatic drugs for venous thrombosis in Behcet\u2019s syndrome: a retrospective study of seventy patients with vascular involvement, arthritis","volume":"70","author":"Emmi","year":"2018","journal-title":"Rheumatol"},{"key":"10.1016\/j.clim.2022.109186_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101735","article-title":"Treating-to-target in rheumatology: theory and practice","volume":"36","author":"Duarte","year":"2022","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0455","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rdc.2018.09.007","article-title":"Challenges in implementing treat-to-target strategies in rheumatology","volume":"45","author":"Ford","year":"2019","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.clim.2022.109186_bb0460","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2022.109186_bb0465","first-page":"1967","article-title":"Damage accrual in rheumatoid arthritis: evaluating the joint and beyond, arthritis","volume":"72","author":"Fragoulis","year":"2020","journal-title":"Rheumatol"},{"key":"10.1016\/j.clim.2022.109186_bb0470","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the systemic Lupus international collaborating clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2022.109186_bb0475","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/BOR.0000000000000854","article-title":"A treat-to-target approach is needed for Behcet\u2019s syndrome","volume":"34","author":"Hatemi","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0480","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/BOR.0000000000000699","article-title":"New galaxies in the universe of shared decision-making and rheumatoid arthritis","volume":"32","author":"Barton","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2022.109186_bb0485","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s12325-020-01258-5","article-title":"What matters Most to patients and rheumatologists? A discrete choice experiment in rheumatoid arthritis","volume":"37","author":"Diaz-Torne","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.clim.2022.109186_bb0490","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Behcet's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2022.109186_bb0495","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14728214.2020.1847271","article-title":"Cakar Ozdal, Behcet's disease uveitis: is there a need for new emerging drugs?","volume":"25","author":"Tugal-Tutkun","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"issue":"8","key":"10.1016\/j.clim.2022.109186_bb0500","first-page":"1575","article-title":"IL-6 blockade for Beh\u00e7et\u2019s disease: review on 31 anti-TNF na\u00efve and 45 anti-TNF experienced patients","volume":"40","author":"Arida","year":"2022","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622002674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622002674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:09:59Z","timestamp":1761494999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661622002674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":99,"alternative-id":["S1521661622002674"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2022.109186","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat to target in Behcet's disease: Should we follow the paradigm of other systemic rheumatic diseases?","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2022.109186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109186"}}